A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma (EDURO)
view all Clinical Trials
This study will test the efficacy of omalizumab compared with placebo on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week double-blind treatment period, and a 4-week safety follow-up. Approximately 150 participants will be randomized at a 2:1 ratio to omalizumab and placebo, respectively.
This trial is not currently open for enrollment, but it is expected to re-open at a later date. For more information about this trial or to inquire about eligibility, email email@example.com or call 215-707-1359.